Otonomy

Otonomy Liabilities

Delisted

The The Liabilities of Otonomy (OTIC) as of Nov 10, 2026 is 40.73 M USD. In the previous year, The Liabilities was 40.00 M USD — a change of 1.82% (higher).

Liabilities

40.73 MUSD

YoY

1.82%

Last updated:

In 2021, Otonomy's total liabilities amounted to 40.73 M USD, a 1.82% difference from the 40.00 M USD total liabilities in the previous year.

The Otonomy Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2014
5.60 M USD
Jan 1, 2015
11.50 M USD
Jan 1, 2016
15.90 M USD
Jan 1, 2017
11.10 M USD
Jan 1, 2018
25.30 M USD
Jan 1, 2019
42.80 M USD
Jan 1, 2020
40.00 M USD
Jan 1, 2021
40.73 M USD
The Otonomy Liabilities history
YEARLiabilitiesYoY
40.73 MUSD+1.82%
40.00 MUSD-6.54%
42.80 MUSD+69.17%
25.30 MUSD+127.93%
11.10 MUSD-30.19%
15.90 MUSD+38.26%
11.50 MUSD+105.36%
5.60 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Otonomy Stock analysis

What does Otonomy do? Otonomy Inc is a biopharmaceutical company focused on developing innovative therapies for inner ear disorders. The company was founded in 2008 in San Diego, California and has since made significant advancements to bring its products to market. Otonomy's business model is based on identifying unmet medical needs in the field of otolaryngology. The company develops and markets FDA-approved ear medications that are designed in new and innovative ways to improve the treatment of hearing and balance disorders. The different divisions of Otonomy include clinical research, product development, manufacturing, and distribution. The company has an experienced team of scientists, engineers, clinical researchers, and managers who work closely together to develop and bring Otonomy's pipeline of drug candidates to market. The company has launched a number of products targeting the needs of patients with inner ear disorders. For example, the medication Otiprio was developed to treat otitis media, an inflammation of the middle ear. Otiprio is delivered directly into the ear during a minor surgery, where it quickly acts to eliminate the inflammation. Another one of Otonomy's products is Otividex, a medication developed to treat patients with Meniere's disease. This condition is a rare inner ear disorder that causes dizziness, tinnitus, and hearing loss. Otividex is also delivered directly into the ear and has shown to alleviate the dizziness symptoms and improve hearing. In recent years, Otonomy has also developed a new technology called OTO-413, which aims to improve hearing by regenerating damaged hair cells in the inner ear. The company has successfully conducted clinical trials with OTO-413 and plans to further explore and develop the technology. Otonomy has also formed partnerships with other companies and organizations in recent years to further develop its technologies and bring new products to market. For example, the company has entered into a collaboration agreement with Merck to develop new therapies for inner ear disorders. Otonomy also collaborates with a number of academic institutions and research facilities to further explore and develop the potential of its technologies. Overall, Otonomy Inc is an innovative and dynamic company dedicated to developing new therapies for inner ear disorders. With a strong pipeline of drug candidates and a dedicated group of scientists and researchers, the company is well positioned to make significant advancements in the treatment of hearing and balance disorders in the coming years. Otonomy is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Otonomy's Liabilities

Otonomy's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Otonomy's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Otonomy's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Otonomy's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Otonomy’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Otonomy stock

The Liabilities of Otonomy is 40.73 M USD in 2021.

The Liabilities of Otonomy changed from 40.00 M USD to 40.73 M USD, representing a 1.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Otonomy since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Otonomy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Otonomy

All Key Metrics — Otonomy